ArticleDiabetes, obesity, and cardiometabolic CARE
Comparative Effectiveness of Once-Weekly Insulin Efsitora Alfa in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Article in Diabetes, obesity, and cardiometabolic CARE. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAchieving and maintaining a glycated hemoglobin (HbA PURPOSE: The purpose of this analysis is to evaluate the efficacy and safety of once-weekly insulin efsitora alfa compared with once-daily basal insulin in adults with T2D, stratified by baseline insulin use. DATA SOURCES: PubMed, Web of Science, Scopus, and Cochrane CENTRAL were searched from inception through July 2025, along with ClinicalTrials.gov. STUDY SELECTION: Randomized controlled trials (RCTs) enrolling adults with T2D that compared once-weekly insulin efsitora alfa with once-daily basal insulin for ≥12 weeks were included. Six trials met eligibility criteria. DATA EXTRACTION: Two authors independently extracted data using a standardized form. The primary outcome was the mean change in HbA DATA SYNTHESIS: Six RCTs, including 4,116 participants, were analyzed. Efsitora demonstrated HbA LIMITATIONS: All included trials were open-label, and follow-up duration was limited. Long-term outcomes, real-world adherence, and cost-effectiveness could not be fully assessed.
conclusionsOnce-weekly insulin efsitora alfa demonstrates glycemic control and overall safety comparable to once-daily basal insulin in adults with T2D, with fewer nocturnal hypoglycemia episodes. Longer-term RCTs and real-world studies are needed to define its long-term clinical and economic impact.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.